A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)

Investigational New Drugs

Volumn 31, Issue 5, 2013, Pages 1311-1320

  Gupta, Pankaj ^a,i   Mulkey, Flora ^b   Hasserjian, Robert P ^c   Sanford, Ben L ^b   Vij, Ravi ^d   Hurd, David D ^e   Odenike, Olatoyosi M ^f   Bloomfield, Clara D ^g   Owzar, Kouros ^b   Stone, Richard M ^h   Larson, Richard A ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e WAKE FOREST UNIVERSITY   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ VA MEDICAL CENTER   (United States)

Author keywords

(MeSH): Angiogenesis inhibitors; Humans; Myelodysplastic syndromes; Treatment outcome; Vascular endothelial growth factor

Indexed keywords

VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; ATAXIA; BLOOD CELL COUNT; BRAIN HEMORRHAGE; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; INFECTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LETHARGY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MALIGNANT TRANSFORMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; SUDDEN DEATH; THROMBOCYTE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHTHALAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84884813690     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9978-z     Document Type: Article

References (37)

1. Scott BL, Deeg HJ (2010) Myelodysplastic syndromes. Annu Rev Med 61:345-358
2. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96(6):2240-2245
3. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF et al (1999) Angiogenesis in myelodysplastic syndromes. Br J Cancer 81(8):1398-1401
4. Verstovsek S, Estey E, Giles FJ, Manshouri T, Beran M, Rogers A et al (2000) Clinical relevance of VEGF receptors 1 and 2 in AML and MDS. Blood 96(11):103a
5. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M et al (1999) Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94(11):3717-3721
6. Bellamy WT, Richter L, Frutiger Y, Grogan TM (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59:728-733
7. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y et al (2001) Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97(5):1427-1434
8. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M et al (1997) Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89(6):1870-1875
9. Ratajczak MZ, Ratajczak J, Machalinski B, Majka M, Marlicz W, Carter A et al (1998) Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PlGF) in regulating human haemopoietic cell growth. Br J Haematol 103(4):969-979
10. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-Alpha from cells. Nature 385(6618):729-733
11. Gupta P, Niehans GA, LeRoy SC, Gupta K, Morrison VA, Schultz C et al (1999) Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia 13(1):44-53
12. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S et al (1995) Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182(6):1777-1783
13. Solanilla A, Grosset C, Lemercier C, Dupouy M, Mahon FX, Schweitzer K et al (2000) Expression of Flt3-ligand by the endothelial cell. Leukemia 14(1):153-162
14. Yamaguchi H, Ishii E, Saito S, Tashiro K, Fujita I, Yoshidomi S et al (1996) Umbilical vein endothelial cells are an important source of c-kit and stem cell factor which regulate the proliferation of haemopoietic progenitor cells. Br J Haematol 94(4):606-611
15. Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P et al (2000) New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor- driven angiogenesis. J Med Chem 43(12):2310-2323
16. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M et al (2000) Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60(17):4819-4824
17. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J et al (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60(8):2178-2189
18. George D, Michaelson D, Oh WK, Reitsma D, Laurent D, Mietlowski W et al. (2003) Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma Proc Am Soc Clin Oncol 22:abstr 1548
19. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21(21):3955-3964
20. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. IARC Press, Lyon, France
21. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA et al (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18(20):3558-3585
22. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96(12):3671-3674
23. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079-2088
24. Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M et al (2006) Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 20(6):952-957
25. Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, Wang X et al (2012) Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 76(3):393-396
26. Joensuu H, De Braud F, Grignagni G, De Pas T, Spitalieri G, Coco P et al (2011) Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 104(11):1686-1690
27. Mross K, Drevs J, Muller M, Medinger M, Marme D, Hennig J et al (2005) Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 41(9):1291-1299
28. Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL et al (2007) PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res 31(7):891-897
29. Cook N, Basu B, Biswas S, Kareclas P, Mann C, Palmer C et al (2010) A phase 2 study of vatalanib in metastatic melanoma patients. Eur J Cancer 46(15):2671-2673
30. Gauler TC, Besse B, Mauguen A, Meric JB, Gounant V, Fischer B et al (2012) Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol 23(3):678-687
31. Vij R, Ansstas G, Mosley JC, Bryant G, Hassan A, Amador-Ortiz C et al (2010) Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant. Leuk Lymphoma 51(8):1577-1579
32. Gupta P, Miller AA, Owzar K, Murry DJ, Sanford BL, Vij R et al (2006) Pharmacokinetics of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B Study 10105. J Clin Oncol 24(18S):6573 (abstr)
33. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L et al (2005) Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23(18):4162-4171
34. Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA et al (2011) Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29(15):1997-2003
35. Van Cutsem E, Bajetta E, Valle J, Kohne CH, Hecht JR, Moore M et al (2011) Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29(15):2004-2010
36. Legros L, Slama B, Karsenti JM, Vey N, Natarajan-Ame S, Watel E et al (2012) Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. Ann Hematol 91(1):39-46
37. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL et al (2003) SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102(3):795-801